IMV.TO - IMV Inc.

Toronto - Toronto Delayed Price. Currency in CAD
6.39
+0.08 (+1.27%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close6.31
Open6.46
Bid6.21 x 0
Ask6.21 x 0
Day's Range6.23 - 6.48
52 Week Range3.33 - 9.49
Volume29,188
Avg. Volume72,687
Market Cap286.837M
Beta3.43
PE Ratio (TTM)N/A
EPS (TTM)-0.32
Earnings DateAug 8, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.55
  • ACCESSWIRE11 days ago

    Today's Research Reports on Acerus Pharmaceuticals, IMV, Valeant Pharmaceuticals and BELLUS Health

    NEW YORK, NY / ACCESSWIRE / July 9, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...

  • GlobeNewswirelast month

    IMV Inc. Appoints Julia P. Gregory to Board of Directors

    IMV Inc. (“IMV” or the “Corporation”) (IMV) (IMV.TO), a clinical stage immunotherapy company, announced today the addition of Julia P. Gregory to the company’s Board of Directors. Andy Sheldon, IMV Chairman of the Board, commented, “Julia’s experience is an ideal addition to our Board given the Company’s anticipated near-term milestones and long-term strategic vision.

  • ACCESSWIRElast month

    Today's Research Reports on Resverlogix, Aphria, IMV and Oncolytics Biotech

    NEW YORK, NY / ACCESSWIRE / June 5, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...

  • GlobeNewswire2 months ago

    IMV Inc. (Formerly Immunovaccine Inc.) Presents New Positive Data From Phase 1b/2 Combination Clinical Trial in Advanced Ovarian Cancer at 2018 ASCO Meeting

    IMV Inc. (IMV.TO) (IMV.TO), a clinical stage immuno-oncology corporation, today announced that investigators shared new positive data in an oral presentation for its DeCidE1 (DPX-Survivac with low dose CyclophosphamIDe and Epacadostat) clinical study at the 2018 American Society for Clinical Oncology (ASCO) annual meeting. During the presentation, Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, provided an update on the clinical benefits from the first 18 evaluable participants among 26 enrolled (including 10 from 100mg epacadostat dosing cohort and 8 from 300mg epacadostat cohort), as well as blood sample and tumor biopsy analyses from the study’s first dosing cohort.

  • GlobeNewswire2 months ago

    Nasdaq Approves Listing of IMV Inc. Common Shares

    IMV Inc. (“IMV” or the “Corporation”) (IMV.TO) (IMMVD), a clinical stage immunotherapy company, today announced that its common shares have been approved for listing on the Nasdaq Capital Market under the symbol "IMV." Trading will commence as early as Friday, June 1, 2018. The Corporation will retain its listing on the Toronto Stock Exchange under the symbol "IMV" and the company's common shares will continue to trade on the OTCQX under the symbol “IMMVD” until trading on the Nasdaq commences. Frederic Ors, IMV Chief Executive Officer, commented, “On the heels of recent progress we have made in positioning and validating IMV’s unique value proposition in immuno-oncology, listing on Nasdaq affords us the opportunity to attract more institutional investors, broaden our shareholder base, and improve liquidity.

  • GlobeNewswire2 months ago

    IMV Leadership to Participate in Upcoming Investor and Business Development Conferences

    HALIFAX, Nova Scotia, May 30, 2018-- IMV Inc., a clinical stage immuno-oncology company, today announced details on upcoming industry presentations that the company’ s leadership will be making at the ...

  • GlobeNewswire2 months ago

    IMV (Formerly Immunovaccine Inc.) to Present at the National Bank Financial Quebec Conference in Toronto

    HALIFAX, Nova Scotia, May 25, 2018-- IMV Inc., a clinical stage immuno-oncology company, today announced that IMV Chief Executive Officer Frederic Ors will present a corporate update at the National Bank ...

  • GlobeNewswire2 months ago

    IMV Inc. (Formerly Immunovaccine Inc.) Announces Q1 2018 Financial Results

    IMV Inc. (IMV.TO) (IMMVD), a clinical stage immuno-oncology corporation, today released its financial and operational results for the first quarter ended March 31, 2018. “In continuing to deliver value to our shareholders and partners, IMV has made remarkable progress this quarter in validating our potential in immuno-oncology. “These achievements have significantly advanced our programs, and together with our anticipated milestones – including our oral presentation at this year’s ASCO conference as well as early data read-outs from our Phase 2 combination trials with Merck, we look forward to further advancing DPX-Survivac in the immunotherapy clinical landscape.

  • Baystreet2 months ago

    Stocks in play: IMV Inc.

    Announced that its common shares commence trading post consolidation today. The consolidation has been ...

  • GlobeNewswire2 months ago

    IMV Inc. – Change of ticker on OTCQX from IMMVF to IMMVD

    HALIFAX, Nova Scotia, May 10, 2018-- IMV Inc., a clinical stage immunotherapy company, announced that its new ticker on OTCQX following share consolidation is now IMMVD.. IMV Inc. is a clinical stage biopharmaceutical ...

  • GlobeNewswire2 months ago

    IMV Inc. Commences Trading on the TSX and OTCQX Post-Reverse Stock Split

    As announced on May 3, 2018, the consolidation has been done on the basis of one new common share for every 3.2 outstanding common shares. The consolidation has taken effect on May 2, 2018, and the Corporation's common shares commence trading on the Toronto Stock Exchange and on the OTCQX under the name IMV Inc. on a post-consolidation basis at the open of markets today.

  • GlobeNewswire3 months ago

    Immunovaccine Inc. Has Applied to List its Common Shares on Nasdaq, Announces Reverse Stock Split

    Immunovaccine Inc. (“Immunovaccine” or the “Corporation”) (IMV.TO) (IMMVF), a clinical stage immunotherapy company, announced today that it has applied to list its common shares on the Nasdaq Stock Market LLC ( “Nasdaq”). In connection with the planned U.S. listing, and as previously authorized by its shareholders, the Corporation is implementing a consolidation of its outstanding common shares, and changing the Corporation name to IMV Inc. "In an effort to deliver value to our shareholders and partners, our Company has made remarkable progress in positioning and validating our unique value proposition in immuno-oncology,” said Frederic Ors, Immunovaccine's Chief Executive Officer.

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Fennec Pharmaceuticals, Aptose Biosciences, TSO3 and ImmunoVaccine

    NEW YORK, NY / ACCESSWIRE / May 2, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...

  • GlobeNewswire3 months ago

    Immunovaccine Shareholders Approve Share Consolidation at 99.85%

    Immunovaccine Inc. (IMV.TO)(IMMVF), a clinical stage immuno-oncology corporation, today announced that at the annual and special meeting of shareholders held on May 1, 2018, the share consolidation as described in the management information circular filed on April 4, 2018 (the “Circular”) was approved by the shareholders at 99.85% of the shares voted. “As our Company continues to evolve, getting closer to bringing a new class of immunotherapies to patients in disease areas with unmet or under-served medical needs, we have the opportunity to broaden our investor base and further bolster our financial position,” said Frederic Ors, Chief Executive Officer, Immunovaccine Inc.

  • ACCESSWIRE3 months ago

    Stonegate Capital Partners Initiates Coverage on ImmunoVaccine, Inc. (TSX: IMV)

    DALLAS, TX / ACCESSWIRE / April 30, 2018 / Stonegate Capital Partners has initiated research coverage on ImmunoVaccine, Inc. (TSX: IMV) (OTCQX: IMMVF). Despite ongoing advancements in the development of ...

  • GlobeNewswire3 months ago

    Immunovaccine to Highlight Clinical Data for Its Lead Candidate in Oral Presentation at 54th Annual Meeting of the American Society of Clinical Oncology

    HALIFAX, Nova Scotia, April 26, 2018-- Immunovaccine Inc., a clinical stage immuno-oncology company, today announced that its abstract has been selected for an oral presentation at the upcoming 2018 American ...

  • GlobeNewswire3 months ago

    Immunovaccine and Incyte Expand Clinical Collaboration Evaluating Combination Immunotherapies in Advanced Recurrent Ovarian Cancer

    Immunovaccine Inc. (IMV.TO) (IMMVF), a clinical stage immuno-oncology company, today announced that it has entered into an agreement with Incyte Corporation to expand their ongoing clinical trial collaboration. The Companies plan to add a Phase 2 component to their ongoing Phase 1b combination study evaluating the safety and efficacy of Immunovaccine’s lead candidate, DXP-Survivac, in combination with Incyte’s IDO1 enzyme inhibitor epacadostat and low dose cyclophosphamide in advanced ovarian cancer patients.

  • GlobeNewswire3 months ago

    Immunovaccine to Present at Bloom Burton & Co. Healthcare Investor Conference

    HALIFAX, Nova Scotia, April 23, 2018-- Immunovaccine Inc., a clinical stage immuno-oncology company, announced that Chief Executive Officer Frederic Ors will present an update on the Company's recent progress ...

  • ACCESSWIRE3 months ago

    Research Reports on Aurinia Pharma, Immunovaccine, IntelliPharmaCeutics International, and OrganiGram Holdings

    LONDON, UK / ACCESSWIRE / April 12, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: Aurinia Pharmaceuticals, Immunovaccine, ...

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Acerus Pharmaceuticals, TSO3, BELLUS Health and ImmunoVaccine

    NEW YORK, NY / ACCESSWIRE / April 5, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...